DUBLIN, March 26, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced it has completed the acquisition of Envy Medical, Inc., a privately held company with proprietary technology in skin resurfacing. The acquisition enhances Allergan's best-in-class Medical Aesthetics portfolio with the addition of Envy's Dermalinfusion, a non-surgical, non-invasive skin resurfacing system for the face and body. Offered in physician's offices, medical spas and luxury spas, Dermalinfusion is the only treatment that simultaneously exfoliates, extracts and infuses the skin with professional strength serums, using medical grade diamond treatment tips. Each serum is specifically formulated to help treat a variety of skin concerns across all skin types.
"The acquisition of Envy Medical's Dermalinfusion reinforces our commitment to skin care and to offering a full range of solutions for Allergan customers and consumers. The breakthrough technology for skin resurfacing appeals to millennials and their focus on skin quality and is a perfect opportunity for Allergan to help our healthcare providers capture new patients for this and other medical aesthetic procedures," said Carrie Strom, Senior Vice President, U.S. Medical Aesthetics at Allergan.
Envy Medical CEO Arash Khazei added, "As a leader in non-invasive medical aesthetic devices, we believe the Dermalinfusion system is a perfect fit with Allergan and its product portfolio. We have always looked to broaden awareness and reach of Dermalinfusion, and Allergan's commitment to innovation, brand development, and global market expansion is perfectly aligned with our vision. We are very excited to join Allergan."
In addition to Dermalinfusion systems and serums, Envy offers a complete line of proprietary, take-home skin care products promoting healthy skin. These products will further complement Allergan's SkinMedica® portfolio of innovative skin care products.
About Dermalinfusion
Dermalinfusion is a non-surgical, non-invasive skin resurfacing system for the face and body. Dermalinfusion simultaneously exfoliates, extracts and infuses the skin with professional strength serums designed to help treat a variety of skin concerns across skin types. The proprietary technology uses medical grade diamond tips to safely and effectively exfoliate all skin types. Dermalinfusion is available in physician's offices, medical spas and luxury spas in the United States and globally with an installed base of over 3,800 units. Internationally, Dermalinfusion is sold in over 30 countries through a network of third party distributors.
About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical leader. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.
Allergan markets a portfolio of leading brands and best-in-class products primarily focused on four key therapeutic areas including medical aesthetics, eye care, central nervous system and gastroenterology.
Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry.
Allergan's success is powered by our global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.
With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.
For more information, visit Allergan's website at www.Allergan.com.
Forward-Looking Statement
Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; risks associated with divestitures, acquisitions, mergers and joint ventures; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2018. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.
CONTACTS: Allergan:
Investors:
Manisha Narasimhan, PhD
(862) 261-7162
Christine Chiou
(862) 261-7396
Media:
Amy Rose
(862) 289-3072
Lisa Brown
(862) 261-7320
